Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibody
Authors:
- John W. RoseJRJohn W. Rose
- Hilary E. WattHWHilary E. Watt
- Andrea T. WhiteAWAndrea T. White
- 20 October 2004
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 56 (6) , 864-867
Abstract
We examined whether treatment with daclizumab, a humanized monoclonal antibody specific for the interleukin‐2 receptor α chain, was safe and efficacious in relapsing–remitting and secondary progressive multiple sclerosis patients. Nineteen ambulatory patients with clinically active disease were treated for 5 to 25 months. Seventeen patients were not responding to other immunotherapies. Daclizumab was generally well tolerated. Sustained clinical improvement (10 patients) or stabilization (9 patients) was observed. Daclizumab treatment produced significant reduction in magnetic resonance imaging activity. Ann Neurol 2004Keywords
This publication has 10 references indexed in Scilit:
- Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon βProceedings of the National Academy of Sciences, 2004
- Current immunotherapy for demyelinating diseases.Archives of Neurology, 2002
- Advances in interleukin 2 receptor targeted treatmentAnnals of the Rheumatic Diseases, 2000
- Multiple SclerosisNew England Journal of Medicine, 2000
- Emerging Therapies: Spectrum of Applications of Monoclonal Antibody TherapyHematology-American Society Hematology Education Program, 2000
- Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trialProceedings of the National Academy of Sciences, 1999
- Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal TransplantationNew England Journal of Medicine, 1998
- Chimeric cytotoxin IL2-PE40 inhibits relapsing experimental allergic encephalomyelitisJournal of Neuroimmunology, 1991
- Immunotherapy of experimental autoimmune encephalomyelitis (EAE): Differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis ratJournal of Autoimmunity, 1989
- Autoimmune effector cells. IX. Inhibition of adoptive transfer of autoimmune encephalomyelitis with a monoclonal antibody specific for interleukin 2 receptors.The Journal of Immunology, 1987